{"id":477672,"date":"2021-04-19T06:03:36","date_gmt":"2021-04-19T10:03:36","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ideaya-biosciences-announces-agenda-for-inaugural-synthetic-lethality-investor-day-on-tuesday-april-20-2021\/"},"modified":"2021-04-19T06:03:36","modified_gmt":"2021-04-19T10:03:36","slug":"ideaya-biosciences-announces-agenda-for-inaugural-synthetic-lethality-investor-day-on-tuesday-april-20-2021","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ideaya-biosciences-announces-agenda-for-inaugural-synthetic-lethality-investor-day-on-tuesday-april-20-2021\/","title":{"rendered":"IDEAYA Biosciences Announces Agenda for Inaugural Synthetic Lethality Investor Day on Tuesday, April 20, 2021"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">SOUTH SAN FRANCISCO, Calif.<\/span>, <span class=\"xn-chron\">April 19, 2021<\/span> \/PRNewswire\/ &#8212; IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced the agenda for its inaugural Synthetic Lethality Investor Day.\u00a0The event will be held virtually on <span class=\"xn-chron\">Tuesday, April 20, 2021<\/span>, at <span class=\"xn-chron\">1:00 pm &#8211; 3:00 pm ET<\/span> (<span class=\"xn-chron\">10:00 am<\/span> &#8211; 12:00 <span class=\"xn-chron\">noon PT<\/span>).\u00a0The agenda will include scientific presentations from IDEAYA, GlaxoSmithKline (GSK) and several key opinion leaders.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/820568\/IDEAYA_Logo.html\" target=\"_blank\" rel=\"nofollow noopener\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/820568\/IDEAYA_Logo.jpg\" title=\"(PRNewsfoto\/IDEAYA Biosciences, Inc.)\" alt=\"(PRNewsfoto\/IDEAYA Biosciences, Inc.)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>\n        <u>Presenters<\/u>\n      <\/p>\n<ul type=\"disc\">\n<li>Alan D&#8217;Andrea, M.D., Director, Center of DNA Damage and Repair, Dana Farber Cancer Institute of <span class=\"xn-org\">Harvard Medical School<\/span><\/li>\n<li>\n          <span class=\"xn-person\">William Sellers<\/span>, M.D., Core Institute Member and Director of the Cancer Program of the Broad Institute of <span class=\"xn-org\">MIT<\/span> and <span class=\"xn-org\">Harvard<\/span><\/li>\n<li>\n          <span class=\"xn-person\">Benjamin Schwartz<\/span>, Ph.D., Vice President, Head of Oncology Synthetic Lethality Research Unit, GlaxoSmithKline (GSK) <\/li>\n<li>\n          <span class=\"xn-person\">Yujiro Hata<\/span>, President and Chief Executive Officer, IDEAYA Biosciences <\/li>\n<li>\n          <span class=\"xn-person\">Michael Dillon<\/span>, Ph.D., SVP and Chief Scientific Officer, IDEAYA Biosciences <\/li>\n<li>\n          <span class=\"xn-person\">Mark Lackner<\/span>, Ph.D., SVP and Head of Biology and Translational Sciences, IDEAYA Biosciences <\/li>\n<li>\n          <span class=\"xn-person\">Matt Maurer<\/span>, M.D., VP and Head of Clinical Oncology and Medical Affairs, IDEAYA Biosciences<\/li>\n<\/ul>\n<p>\n        <u>Program Agenda (ET)<\/u>\n      <\/p>\n<ul type=\"disc\">\n<li>\n          <span class=\"xn-chron\">1:00 pm<\/span> &#8211; Welcome and Introduction <\/li>\n<ul type=\"circle\">\n<li>\n            <span class=\"xn-person\">Yujiro Hata<\/span>\n          <\/li>\n<\/ul>\n<li>\n          <span class=\"xn-chron\">1:10 pm<\/span> &#8211; Synthetic Lethality: Emerging Area within Precision Medicine and GSK-IDEAYA Partnership <\/li>\n<ul type=\"circle\">\n<li>\n            <span class=\"xn-person\">Ben Schwartz<\/span> (GSK) <\/li>\n<\/ul>\n<li>\n          <span class=\"xn-chron\">1:20 pm<\/span> &#8211; IDE397: Targeting MAT2A in MTAP-Deleted Tumors <\/li>\n<ul type=\"circle\">\n<li>\n            <span class=\"xn-person\">Bill Sellers<\/span> (Broad), <span class=\"xn-person\">Mark Lackner<\/span>, <span class=\"xn-person\">Matt Maurer<\/span><\/li>\n<\/ul>\n<li>\n          <span class=\"xn-chron\">1:50 pm<\/span> &#8211; Werner Helicase (Roundtable): Compelling Synthetic Lethality Target <\/li>\n<ul type=\"circle\">\n<li>Introduction: <span class=\"xn-person\">Ben Schwartz<\/span> (GSK) <\/li>\n<li>Panelists:Bill Sellers (Broad), <span class=\"xn-person\">Mike Dillon<\/span>, <span class=\"xn-person\">Ben Schwartz<\/span><\/li>\n<li>Moderator: <span class=\"xn-person\">Yujiro Hata<\/span><\/li>\n<\/ul>\n<li>\n          <span class=\"xn-chron\">2:10 pm<\/span> &#8211; Pol Theta: Key Target in MMEJ DNA Damage Repair Pathway <\/li>\n<ul type=\"circle\">\n<li>Alan D&#8217;Andrea (<span class=\"xn-org\">Harvard<\/span>), <span class=\"xn-person\">Mike Dillon<\/span>, <span class=\"xn-person\">Ben Schwartz<\/span> (GSK) <\/li>\n<\/ul>\n<li>\n          <span class=\"xn-chron\">2:30 pm<\/span> &#8211; PARG: Novel Target in Clinically Validated Pathway <\/li>\n<ul type=\"circle\">\n<li>\n            <span class=\"xn-person\">Mike Dillon<\/span>, <span class=\"xn-person\">Mark Lackner<\/span><\/li>\n<\/ul>\n<li>\n          <span class=\"xn-chron\">2:45 pm<\/span> &#8211; Analyst Q&amp;A \/ Closing <\/li>\n<ul type=\"circle\">\n<li>\n            <span class=\"xn-person\">Yujiro Hata<\/span>\n          <\/li>\n<\/ul>\n<li>\n          <span class=\"xn-chron\">3:00 pm<\/span> &#8211; Adjourn<\/li>\n<\/ul>\n<p>Registration for the IDEAYA Synthetic Lethality Investor Day and additional information on the event is available on IDEAYA&#8217;s website at <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3132532-1&amp;h=153765844&amp;u=https%3A%2F%2Fir.ideayabio.com%2Fevents&amp;a=https%3A%2F%2Fir.ideayabio.com%2Fevents\" rel=\"nofollow noopener\">https:\/\/ir.ideayabio.com\/events<\/a>. <\/p>\n<p>\n        <b>About IDEAYA Biosciences<br \/><\/b>IDEAYA is a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics.\u00a0IDEAYA&#8217;s approach integrates capabilities in identifying and validating translational biomarkers with drug discovery to select patient populations most likely to benefit from its targeted therapies. IDEAYA is applying its early research and drug discovery capabilities to synthetic lethality \u2013 which represents an emerging class of precision medicine targets.\u00a0 <\/p>\n<p>\n        <b>Forward-Looking Statements<br \/><\/b>This press release contains forward-looking statements, including, but not limited to, statements related to the timing, content and participants of the Synthetic Lethality Investor Day. Such forward-looking statements involve substantial risks and uncertainties that could cause IDEAYA&#8217;s preclinical and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including IDEAYA&#8217;s programs&#8217; early stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, IDEAYA&#8217;s ability to successfully establish, protect and defend its intellectual property, the effects on IDEAYA&#8217;s business of the worldwide COVID-19 pandemic, and other matters that could affect the sufficiency of existing cash to fund operations. IDEAYA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of IDEAYA in general, see the IDEAYA Annual Report for the year ended <span class=\"xn-chron\">December 31, 2020<\/span> on Form 10-K filed on <span class=\"xn-chron\">March 23, 2021<\/span> and any current and periodic reports filed with the U.S. Securities and Exchange Commission.\u00a0\u00a0\u00a0<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder2\"><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=AQ46145&amp;sd=2021-04-19\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/ideaya-biosciences-announces-agenda-for-inaugural-synthetic-lethality-investor-day-on-tuesday-april-20-2021-301271007.html\">http:\/\/www.prnewswire.com\/news-releases\/ideaya-biosciences-announces-agenda-for-inaugural-synthetic-lethality-investor-day-on-tuesday-april-20-2021-301271007.html<\/a><\/p>\n<p>SOURCE  IDEAYA Biosciences, Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=AQ46145&amp;Transmission_Id=202104190600PR_NEWS_USPR_____AQ46145&amp;DateId=20210419\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire SOUTH SAN FRANCISCO, Calif., April 19, 2021 \/PRNewswire\/ &#8212; IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced the agenda for its inaugural Synthetic Lethality Investor Day.\u00a0The event will be held virtually on Tuesday, April 20, 2021, at 1:00 pm &#8211; 3:00 pm ET (10:00 am &#8211; 12:00 noon PT).\u00a0The agenda will include scientific presentations from IDEAYA, GlaxoSmithKline (GSK) and several key opinion leaders. Presenters Alan D&#8217;Andrea, M.D., Director, Center of DNA Damage and Repair, Dana Farber Cancer Institute of Harvard Medical School William Sellers, M.D., Core Institute Member and Director of the Cancer Program of the Broad Institute of MIT and Harvard Benjamin Schwartz, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ideaya-biosciences-announces-agenda-for-inaugural-synthetic-lethality-investor-day-on-tuesday-april-20-2021\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;IDEAYA Biosciences Announces Agenda for Inaugural Synthetic Lethality Investor Day on Tuesday, April 20, 2021&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-477672","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>IDEAYA Biosciences Announces Agenda for Inaugural Synthetic Lethality Investor Day on Tuesday, April 20, 2021 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ideaya-biosciences-announces-agenda-for-inaugural-synthetic-lethality-investor-day-on-tuesday-april-20-2021\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IDEAYA Biosciences Announces Agenda for Inaugural Synthetic Lethality Investor Day on Tuesday, April 20, 2021 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire SOUTH SAN FRANCISCO, Calif., April 19, 2021 \/PRNewswire\/ &#8212; IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced the agenda for its inaugural Synthetic Lethality Investor Day.\u00a0The event will be held virtually on Tuesday, April 20, 2021, at 1:00 pm &#8211; 3:00 pm ET (10:00 am &#8211; 12:00 noon PT).\u00a0The agenda will include scientific presentations from IDEAYA, GlaxoSmithKline (GSK) and several key opinion leaders. Presenters Alan D&#8217;Andrea, M.D., Director, Center of DNA Damage and Repair, Dana Farber Cancer Institute of Harvard Medical School William Sellers, M.D., Core Institute Member and Director of the Cancer Program of the Broad Institute of MIT and Harvard Benjamin Schwartz, &hellip; Continue reading &quot;IDEAYA Biosciences Announces Agenda for Inaugural Synthetic Lethality Investor Day on Tuesday, April 20, 2021&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ideaya-biosciences-announces-agenda-for-inaugural-synthetic-lethality-investor-day-on-tuesday-april-20-2021\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-04-19T10:03:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/820568\/IDEAYA_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ideaya-biosciences-announces-agenda-for-inaugural-synthetic-lethality-investor-day-on-tuesday-april-20-2021\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ideaya-biosciences-announces-agenda-for-inaugural-synthetic-lethality-investor-day-on-tuesday-april-20-2021\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"IDEAYA Biosciences Announces Agenda for Inaugural Synthetic Lethality Investor Day on Tuesday, April 20, 2021\",\"datePublished\":\"2021-04-19T10:03:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ideaya-biosciences-announces-agenda-for-inaugural-synthetic-lethality-investor-day-on-tuesday-april-20-2021\\\/\"},\"wordCount\":641,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ideaya-biosciences-announces-agenda-for-inaugural-synthetic-lethality-investor-day-on-tuesday-april-20-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/820568\\\/IDEAYA_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ideaya-biosciences-announces-agenda-for-inaugural-synthetic-lethality-investor-day-on-tuesday-april-20-2021\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ideaya-biosciences-announces-agenda-for-inaugural-synthetic-lethality-investor-day-on-tuesday-april-20-2021\\\/\",\"name\":\"IDEAYA Biosciences Announces Agenda for Inaugural Synthetic Lethality Investor Day on Tuesday, April 20, 2021 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ideaya-biosciences-announces-agenda-for-inaugural-synthetic-lethality-investor-day-on-tuesday-april-20-2021\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ideaya-biosciences-announces-agenda-for-inaugural-synthetic-lethality-investor-day-on-tuesday-april-20-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/820568\\\/IDEAYA_Logo.jpg\",\"datePublished\":\"2021-04-19T10:03:36+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ideaya-biosciences-announces-agenda-for-inaugural-synthetic-lethality-investor-day-on-tuesday-april-20-2021\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ideaya-biosciences-announces-agenda-for-inaugural-synthetic-lethality-investor-day-on-tuesday-april-20-2021\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ideaya-biosciences-announces-agenda-for-inaugural-synthetic-lethality-investor-day-on-tuesday-april-20-2021\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/820568\\\/IDEAYA_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/820568\\\/IDEAYA_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ideaya-biosciences-announces-agenda-for-inaugural-synthetic-lethality-investor-day-on-tuesday-april-20-2021\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"IDEAYA Biosciences Announces Agenda for Inaugural Synthetic Lethality Investor Day on Tuesday, April 20, 2021\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"IDEAYA Biosciences Announces Agenda for Inaugural Synthetic Lethality Investor Day on Tuesday, April 20, 2021 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ideaya-biosciences-announces-agenda-for-inaugural-synthetic-lethality-investor-day-on-tuesday-april-20-2021\/","og_locale":"en_US","og_type":"article","og_title":"IDEAYA Biosciences Announces Agenda for Inaugural Synthetic Lethality Investor Day on Tuesday, April 20, 2021 - Market Newsdesk","og_description":"PR Newswire SOUTH SAN FRANCISCO, Calif., April 19, 2021 \/PRNewswire\/ &#8212; IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced the agenda for its inaugural Synthetic Lethality Investor Day.\u00a0The event will be held virtually on Tuesday, April 20, 2021, at 1:00 pm &#8211; 3:00 pm ET (10:00 am &#8211; 12:00 noon PT).\u00a0The agenda will include scientific presentations from IDEAYA, GlaxoSmithKline (GSK) and several key opinion leaders. Presenters Alan D&#8217;Andrea, M.D., Director, Center of DNA Damage and Repair, Dana Farber Cancer Institute of Harvard Medical School William Sellers, M.D., Core Institute Member and Director of the Cancer Program of the Broad Institute of MIT and Harvard Benjamin Schwartz, &hellip; Continue reading \"IDEAYA Biosciences Announces Agenda for Inaugural Synthetic Lethality Investor Day on Tuesday, April 20, 2021\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ideaya-biosciences-announces-agenda-for-inaugural-synthetic-lethality-investor-day-on-tuesday-april-20-2021\/","og_site_name":"Market Newsdesk","article_published_time":"2021-04-19T10:03:36+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/820568\/IDEAYA_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ideaya-biosciences-announces-agenda-for-inaugural-synthetic-lethality-investor-day-on-tuesday-april-20-2021\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ideaya-biosciences-announces-agenda-for-inaugural-synthetic-lethality-investor-day-on-tuesday-april-20-2021\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"IDEAYA Biosciences Announces Agenda for Inaugural Synthetic Lethality Investor Day on Tuesday, April 20, 2021","datePublished":"2021-04-19T10:03:36+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ideaya-biosciences-announces-agenda-for-inaugural-synthetic-lethality-investor-day-on-tuesday-april-20-2021\/"},"wordCount":641,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ideaya-biosciences-announces-agenda-for-inaugural-synthetic-lethality-investor-day-on-tuesday-april-20-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/820568\/IDEAYA_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ideaya-biosciences-announces-agenda-for-inaugural-synthetic-lethality-investor-day-on-tuesday-april-20-2021\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ideaya-biosciences-announces-agenda-for-inaugural-synthetic-lethality-investor-day-on-tuesday-april-20-2021\/","name":"IDEAYA Biosciences Announces Agenda for Inaugural Synthetic Lethality Investor Day on Tuesday, April 20, 2021 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ideaya-biosciences-announces-agenda-for-inaugural-synthetic-lethality-investor-day-on-tuesday-april-20-2021\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ideaya-biosciences-announces-agenda-for-inaugural-synthetic-lethality-investor-day-on-tuesday-april-20-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/820568\/IDEAYA_Logo.jpg","datePublished":"2021-04-19T10:03:36+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ideaya-biosciences-announces-agenda-for-inaugural-synthetic-lethality-investor-day-on-tuesday-april-20-2021\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ideaya-biosciences-announces-agenda-for-inaugural-synthetic-lethality-investor-day-on-tuesday-april-20-2021\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ideaya-biosciences-announces-agenda-for-inaugural-synthetic-lethality-investor-day-on-tuesday-april-20-2021\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/820568\/IDEAYA_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/820568\/IDEAYA_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ideaya-biosciences-announces-agenda-for-inaugural-synthetic-lethality-investor-day-on-tuesday-april-20-2021\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"IDEAYA Biosciences Announces Agenda for Inaugural Synthetic Lethality Investor Day on Tuesday, April 20, 2021"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/477672","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=477672"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/477672\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=477672"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=477672"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=477672"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}